返回 
加入收藏
维得利珠单抗相关肺毒性1例并文献分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 维得利珠单抗相关肺毒性1例并文献分析 |
| TITLE： | Vedolizumab-associated lung toxicity：a case report and literature analysis |
| 摘要： | 目的 介绍1例维得利珠单抗（VDZ）致间质性肺炎的病例，汇总分析该药相关肺毒性的发生特点，为临床安全用药提供参考。方法从临床药师角度出发，回顾性分析1例VDZ致间质性肺炎患者的诊治过程，并进行不良反应相关性分析；检索中国知网、维普网、PubMed、WebofScience等中英文数据库，对VDZ相关肺毒性的病例报道进行汇总分析。结果该患者在使用VDZ期间发生间质性肺炎，予抗菌药物经验性抗感染治疗无改善；停用VDZ并予甲泼尼龙治疗后，患者的症状及影像学检查均有改善但仍提示间质性肺炎。经Naranjo’s不良反应评估量表评估并根据我国《药品不良反应报告和监测工作手册》判断，VDZ与间质性肺炎的关联性均为“很可能”。文献分析结果显示，纳入的29例患者（含本文报道的患者）中，男性19例、女性10例，平均年龄（49.24±17.06）岁；肺毒性主要包括VDZ相关性肺炎、嗜酸性粒细胞肺炎、肺肉芽肿或坏死性结节、间质性肺损伤等，多发生在用药后24周以内（58.62%），主要临床表现为咳嗽、呼吸困难、发热等；绝大多数患者经停药和/或给予糖皮质激素等治疗后好转或康复，1例患者因呼吸衰竭死亡。结论肺毒性为VDZ较罕见的不良反应，起病隐匿且症状无特异性。一旦患者出现咳嗽、呼吸困难等症状，临床应早期判断、及时停药，并给予糖皮质激素等对症治疗，以保障患者用药安全。 |
| ABSTRACT： | OBJECTIVE To introduce a case of interstitial pneumonia induced by vedolizumab （VDZ）， summarize and analyze the characteristics of the occurrence of VDZ-associated lung toxicity， and provide a reference for the clinically safe use of drugs. METHODS From the perspective of clinical pharmacists， the diagnosis and treatment of a case of VDZ-induced interstitial pneumonia were retrospectively analyzed， and the association of adverse drug reactions （ADR） was analyzed. Retrieving from Chinese and English databases such as CNKI， VIP， PubMed and Web of Science， case reports of VDZ-associated lung toxicity were summarized and analyzed. RESULTS The patient developed interstitial pneumonia during the use of VDZ and empirical anti- infective therapy with antibiotics was ineffective. After withdrawal of VDZ and treatment with methylprednisolone， symptoms and imaging examinations improved， but interstitial pneumonia still existed. According to Naranjo’s ADR evaluation scale and based on China Adverse Drug Reaction Reporting and Monitoring Manual， the association between VDZ and interstitial pneumonia was “very likely”. Results of the literature analysis showed that among 29 involved patients （including the patient reported in this article）， there were 19 males and 10 females， with an average age of （49.24±17.06） years. Lung toxicity mainly included VDZ- associated pneumonia， eosinophilic pneumonia， pulmonary granulomas or necrobiotic nodules， interstitial lung injury， etc.， which mostly occurred ≤24 weeks after medication （58.62%）. The main clinical manifestations included cough， dyspnea and fever. The vast majority of patients improved or recovered after drug withdrawal and/or glucocorticoid treatment， but one patient died of respiratory failure. CONCLUSIONS Lung toxicity is a rare ADR of VDZ with insidious onset and nonspecific symptoms. Once patients experience symptoms such as cough and dyspnea， early diagnosis，timely drug withdrawal，and symptomatic treatment measures such as glucocorticoid should be taken to ensure medication safety. |
| 期刊： | 2024年第35卷第20期 |
| 作者： | 梁瑜；丁雪丽；武军；全香花；赵俊；张传洲；姜曼 |
| AUTHORS： | LIANG Yu，DING Xueli，WU Jun，QUAN Xianghua，ZHAO Jun，ZHANG Chuanzhou，JIANG Man |
| 关键字： | 维得利珠单抗；肺毒性；间质性肺炎；药物不良反应；文献分析 |
| KEYWORDS： | vedolizumab； lung toxicity； interstitial pneumonia； adverse drug reaction； literature analysis |
| 阅读数： | 14 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
